Durham, NC (PRWEB) July 31, 2012
Cancer Advances has developed an intellectual property portfolio that currently holds over 100 United States and worldwide patents related to a lead compound, Polyclonal Antibody Stimulator (PAS) that has been clinically studied in three gastrointestinal cancers. PAS is an active immunotherapeutic that induces antibodies against the hormone, gastrin 17 (G17), and its precursor, (gly)G17, of which there is extensive published evidence for a central role of both of these endogenous compounds in the development and progression of gastrointestinal tumors, as well as other tumors.
Cancer Advances’ companion diagnostic will be used for the detection and quantitation of gastrin hormones which can be found in a biological fluid sample such as blood. The existence of a companion diagnostic will allow oncologists to identify and target patients who will receive the greatest benefit from treatment with PAS. Slowing tumor growth, improving quality of life, and extending survival for patients suffering from a gastrin hormone-mediated disease are all accomplishments that Cancer Advances has continually strived toward in its research.
“We are excited about our current achievements in gastrointestinal cancer research and development. Our outlook remains positive for future developments in this area of study. We aim to make a worldwide, positive impact with this patent and others as we progress in the fight against gastrin-related diseases,” says Lynda Sutton, president of Cancer Advances.
For more information, please contact:
President, Cancer Advances
About Cancer Advances
Cancer Advances is a biotechnology company focused on impacting human health and suppressing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio.
Please visit our product page for more information on what is in development: http://www.canceradvancesinc.com/product.html
# # #